28 results about "Phosphatidyl inositol" patented technology

The invention discloses a lipid composition for preparing extracellular vesicles, which is prepared from the following lipid substances in percentage by mass: 2 to 18 percent of phosphatidylcholine, 2 to 14 percent of phosphatidylethanolamine, 7 to 27 percent of sphingomyelin, 0.5 to 7 percent of ceramide, 1.5 to 2.5 percent of phosphatidylinositol, 30 to 70 percent of cholesterol and 5 to 8 percent of phosphatidylserine, the fatty acid carbon number of the lipid substance satisfies the following conditions: the fatty acid carbon number of phosphatidylcholine is 16-20, the fatty acid carbon number of phosphatidyl ethanolamine is 16-18, the fatty acid carbon number of sphingomyelin is 16-24, the fatty acid carbon number of ceramide is 16-24, the fatty acid carbon number of phosphatidylinositol is 16-20, the fatty acid carbon number of phosphatidylserine is 18-24, and the molar ratio of cholesterol to sphingomyelin is 4-7. The extracellular vesicles are prepared from the lipid composition and used for biomarkers or drug carriers, and efficient oral drug delivery is achieved.

Described herein are compositions comprising a lanthanide (III) modified fatty acid and methods of treating cancer with the composition. In particular, the application includes a lanthanide (III) modified fatty acid is a 9-R′, 10-R″ tri octadecanoate compound. This lanthanide (III) modified fatty acid can be combined with additional therapeutic agents, such as chemotherapeutic agents, radiopharmaceuticals, hormone therapies, CDK inhibitors, epigenetic modulators, selective estrogen receptor modulators, selective estrogen receptor degraders, aromatase inhibitors, phosphatidyl inositol-3-posphate kinase inhibitors, ATP-adenosine axis-targeting agents, signal transduction inhibitors, RAS signaling inhibitors, PI3K inhibitors, arginase inhibitors, HIF inhibitors, AXL inhibitors, PAK4 inhibitors, immunotherapeutic agents, immune checkpoint inhibitors, and agonists of stimulatory or co-stimulatory immune checkpoints.

The application relates to application of phosphatidylinositol and phosphatidylglycerol as metabolic markers for predicting intracranial atherosclerosis progression, and belongs to the technical field of medical biological detection. In the scheme, single-sample MR analysis is carried out by combining RICAS cohort data with external database data, causal correlation between metabolites and ICAS is analyzed, and serum biomarkers phosphatidylinositol PI 18:0 / 22:6 and phosphatidylglycerol PG 18:1 / 18:2 for ICAS occurrence and development are screened out by combining characteristic metabolic changes of ICAS with causal correlation analysis. ICAS progression is collected through prospective follow-up of the RICAS cohort, the correlation between the serum biomarkers and the ICAS progression is established, and it is verified that the serum biomarkers have transformation application value and can be used as a new biomarker for early prediction of ICAS progression and derivation.

The invention relates to a lipid nutritional composition, a product comprising the same and application of the lipid nutritional composition in preparation of a product for promoting structural development of neural stem cells. The lipid nutritional composition comprises: docosahexaenoic acid and / or a metabolic precursor thereof; arachidonic acid and / or a metabolic precursor thereof; and a population of phospholipids consisting of phosphatidylcholine (PC) and / or a metabolic precursor thereof, phosphatidylserine (PS) and / or a metabolic precursor thereof, phosphatidylethanolamine (PE) and / or a metabolic precursor thereof, phosphatidylinositol (PI) and / or a metabolic precursor thereof, and sphingomyelin (SM) and / or a metabolic precursor thereof; wherein the ratio of the molar equivalents of arachidonic acid to the molar equivalents of docosahexaenoic acid, ARA / DHA, is 1-2: 1; and the ratio of the total molar equivalents of the phospholipid population to the molar equivalents of docosahexaenoic acid, PHL / DHA, is 1-8: 1.

The present invention relates to a method of reducing the phospholipid content in an oil or fat composition and polypeptides having PI-specific phospholipase C activity as well as polypeptides having PC, PE-specific phospholipase C activity and combinations thereof capable of catalyzing this reduction. The invention also relates to polynucleotides encoding the polypeptides, nucleic acid constructs, vectors, and host cells comprising the polynucleotides as well as methods of producing and using the polypeptides.

The invention discloses a phospholipid hydrophilic chromatographic separation and evaporative light scattering detection method suitable for liquid milk, milk powder and milk source raw materials. The method comprises the following steps: preparing a sample solution from a sample to be detected; extracting the sample solution by using a solution of chloroform and methanol to obtain subnatant as extract liquor; adding a saturated salt solution into the extract liquor for chromatographic purification, and taking separated lower clear liquid as purified liquid; preparing the purified liquid into a sample introduction liquid; and determining the phospholipid content in the sample injection solution by using a liquid chromatography-evaporative light scattering detector. In the detection method, a sample solution is extracted by using a solution of chloroform and methanol, and a saturated salt solution is added into an extraction solution for chromatographic purification, so that chromatographic peaks are not interfered, and various phospholipids in food can be accurately measured at the same time; the method can be used for simultaneously determining phosphatidylcholine, sphingomyelin, phosphatidyl ethanolamine, phosphatidylserine and phosphatidylinositol in food, and has the advantages of simplicity, rapidness, accuracy, low detection limit and high sensitivity.

The application discloses a biosynthesis gene cluster of a polyene macrolide natural product mandimycin, and a natural product and application of the biosynthesis gene cluster, wherein the nucleotide sequence of the biosynthesis gene cluster is shown as SEQ ID NO. 1, and the compound structural formula of the natural product mandimycin and mandimycin B is shown as formula I and formula II. The natural product mandimycin can target fungal cell membrane phospholipid molecules, especially phosphatidylinositol, cause important ion efflux in fungal cells, and lead to fungal cell death. The natural product mandimycin and mandimycin B have strong in-vivo and in-vitro antibacterial activity and a broad antibacterial spectrum on various WHO-published multiple drug-resistant fungal key pathogens, including candida, aspergillus, cryptococcus, mucor and fusarium.

Provided is a simple and specific means for detecting Listeria monocytogenes and / or Listeria ivanovii. A culture medium for detecting Listeria monocytogenes and / or Listeria ivanovii contains the following components (A), (B), and (C): (A) a chromogenic substance that develops color by being decomposed with β-glucosidase or a fluorogenic substance that emits fluorescence; (B) a chromogenic substance that develops color by being decomposed with phosphatidylinositol-specific phospholipase C or a fluorogenic substance that emits fluorescence; and (C) a sugar.

The present disclosure generally relates to methods of treating diseases or disorders associated with dysfunctional phosphatidylinositol-specific phospholipase Cγ2 (PLCγ2), such as cancer and immune system disorders, using Bruton's tyrosine kinase (BTK) reducing molecules, such as BTK degrader molecules.

The invention discloses a composition for enhancing cool feeling of a nasal cavity, application of the composition and atomized essence, and relates to the technical field of cooling agents. The composition for enhancing the cool feeling of the nasal cavity comprises a cooling agent, glucoside and an activating agent, wherein the activating agent comprises borneol and / or a phospholipid compound; wherein the glucoside comprises a hydrophilic group and a hydrophobic group; the phospholipid compound comprises at least one of lysophosphatidic acid, lysophosphatidylcholine, lysophosphatidylinositol, lysophosphatidylserine and phosphatidylinositol 4, 5 diphosphate. Glucoside is used for intercepting cooling agent molecules and increasing the exposure concentration of the cooling agent in the nasal cavity, so that the cool feeling strength of the nasal cavity is enhanced, borneol and / or phospholipid compounds are / is used as activating agents, the sensitivity of a cool feeling body is enhanced, and the cool feeling strength of the nasal cavity is further enhanced. The composition for enhancing the cool feeling of the nasal cavity can enhance the cool feeling of the nasal cavity in a targeted mode, and the problems that an existing cooling agent composition for atomized essence cannot target the nasal cavity, and the cool feeling intensity is low are solved.

The present disclosure is generally directed to methods of treating a disease or disorder associated with dysfunctional phosphatidylinositol-specific phospholipase Cγ2 (PLCγ2), such as cancers and immune system disorders, using Bruton's tyrosine kinase (BTK) reducing molecules, such as BTK degrader molecules.

This invention, through lipidomics and clinical sample validation, found that prospective follow-up of pre-pregnancy serum samples from women with a history of recurrent pregnancy loss (RPL) revealed that the pre-pregnancy serum levels of phosphatidylinositol PI (18:1 / 18:1) (i.e., PI 36:2), phosphatidylcholine (29:0-6:0) (i.e., PC 35:0), phosphatidylethanolamine (18:1p-18:2) (i.e., PE 36:3p), triglycerides (28:1-10:4-11:2) (i.e., TG 49:7), triglycerides (14:0-18:2-20:5) (i.e., TG 52:7), and wax esters (22:1) (i.e., WE 22:1) were significantly lower in these women than in those who subsequently achieved successful pregnancies. This confirms that the pre-pregnancy serum levels of these six lipids (PI 36:2, PC 35:0, PE 36:3p, TG 49:7, TG 52:7, WE 22:1) were significantly lower in these women than in those who subsequently achieved successful pregnancies. Decreased levels of 22:1 lipids were significantly associated with the risk of miscarriage in subsequent pregnancies. The area under the curve (AUC) of the predictive model constructed by combining six lipids reached 0.85, demonstrating good predictive efficacy. Based on these findings, this lipid combination can serve as a reliable predictor of miscarriage risk in subsequent pregnancies in RPL patients and can be used to develop diagnostic reagents or kits for preconception risk screening.

The invention relates to application of phosphatidylinositol and phosphatidylglycerol as metabolic markers for predicting the progress of intracranial atherosclerosis, and belongs to the technical field of medical biological detection. According to the scheme, RICAS queue data and external database data are combined for single-sample MR analysis, the causal association between metabolites and ICAS is analyzed, ICAS characteristic metabolic change and causal association analysis are combined, serum biomarkers of phosphatidylinositol PI 18: 0 / 22: 6 and phosphatidylglycerol PG 18: 1 / 18: 2 of ICAS occurrence and development are screened out, ICAS progress is collected through prospective follow-up visit of an RICAS queue, and the ICAS development rate is improved. The association between the gene and ICAS progress is established, and the gene has a transformation application value and can be used as a novel biomarker for early prediction of ICAS progress and development.

This invention relates to the treatment of breast cancer in a subject, and the subject can be either a male or female subject. Including methods of: treating metastatic breast cancer; refractory breast cancer; AR-positive breast cancer; AR-positive refractory breast cancer; AR-positive metastatic breast cancer; AR-positive and ER-positive breast cancer; triple negative breast cancer; advanced breast cancer; breast cancer that has failed selective estrogen receptor modulator (SERM) (tamoxifen, toremifene, raloxifene), gonadotropin-releasing hormone (GnRH) agonist (goserelin), aromatase inhibitor (AI) (letrozole, anastrozole, exemestane), cyclin-dependent kinase 4 / 6 (CDK 4 / 6) inhibitor (palbociclib (Ibrance), ribociclib (Kisqali), lerociclib, abemaciclib (Vorzenio), trilaciclib, lerociclib), mTOR inhibitor (everolimus), trastuzumab (Herceptin, ado-trastuzumab emtansine), pertuzumab (Perjeta), alpelisib (Piqray) (an inhibitor of phosphatidylinositol-3-kinase subunit alpha (PI3Kα)), lapatinib, neratinib (Nerlynx), olaparib (Lynparza) (an inhibitor of the enzyme poly ADP ribose polymerase (PARP)), bevacizumab (Avastin), and / or fulvestrant treatments; metastasis in a subject suffering from breast cancer; HER2-positive; treating a subject suffering from ER mutant expressing breast cancer and / or treating breast cancer in a subject, by first determining the 18F-16β-fluoro-5α-dihydrotestosterone (18F-DHT) tumor uptake and identifying said subject as having AR-positive breast cancer based on 18F-DHT tumor uptake, comprising administering to the subject a therapeutically effective amount of a selective androgen receptor modulator (SARM) compound and a cyclin-dependent kinase 4 / 6 (CDK 4 / 6) inhibitor.

The invention belongs to the technical field of microorganisms and medical compounds, and particularly relates to navel orange endophyte Diapothe sp., sesterterpenoids derived from the navel orange endophyte and application of the sesterterpenoids. The navel orange endophyte Diamorpha sp.GC-1-128-79 provided by the invention is preserved in the China Center for Type Culture Collection, and the preservation number of the navel orange endophyte Diamorpha sp.GC-1-128-79 is CCTCC NO: M 20242152. The navel orange endophyte Diapothene sp.GC-1-128-79 provided by the invention can generate a new sesterterpenoid compound through fermentation, and the sesterterpenoid compound can effectively inhibit synthesis of glycosylated phosphatidylinositol, has extremely remarkable antibacterial activity on penicillium italicum, and can be used for preventing and treating citrus penicilliosis.

The present disclosure relates generally to methods of treating diseases or disorders associated with dysfunctional phosphatidylinositol-specific phospholipase C [gamma] 2 (PLC [gamma] 2), such as cancer and immune system disorders, using Bruton's tyrosine kinase (BTK) reducing molecules, such as BTK degrading agent molecules.

A traditional Chinese medicine compound for improving testicular dysfunction is made from the following raw materials: Codonopsis pilosula, Astragalus membranaceus, Dioscorea opposita, Angelica sinensis, Atractylodes macrocephala, Poria cocos, Cynanchum otophyllum, Psoralea corylifolia, Ligusticum chuanxiong, Nelumbo nucifera, Euryale ferox, Amomum villosum, Alpinia katsumadai, Foeniculum vulgare, Cinnamomum cassia, Evodia ruticarpa, Piper nigrum, Zingiber officinale, Aconitum carmichaelii, and Glycyrrhiza uralensis. All the raw materials are combined, so that the spleen, the stomach and the kidney are in harmony, the qi, the blood and the body fluid are recovered, and the kidney essence is active. Animal experiments show that the traditional Chinese medicine compound can up-regulate expressions of phosphatidylinositol 3-kinase (PI3K), phospho-protein kinase B (p-AKT) and B-cell lymphoma-2 (Bcl-2), improve testicular dysfunction, improve hormone secretion, regulate a male reproductive endocrine environment of the body, and further improve semen parameters.

The invention relates to application of dehydroandrographolide in a medicament for preventing and / or treating breast cancer and a pharmaceutical composition of the dehydroandrographolide. According to the application disclosed by the invention, the dehydroandrographolide has the effects of obviously inhibiting the expression of an epidermal growth factor receptor (EGFR) and phosphatidylinositol 3-kinase (PIK3R1) and inhibiting cell migration; the compound has the effects of inhibiting expression of mitogen-activated protein kinase 3 (MAPK3), down-regulating expression of B cell lymphoma / leukemia 2 gene (Bcl-2), increasing expression of Bcl-2 related X protein (Bax) and promoting cell apoptosis, and can be used for preventing or treating breast cancer. The invention aims to provide application of dehydroandrographolide in preventing and treating breast cancer, and further relates to a medication scheme for preventing and treating breast cancer.

The invention provides an application of native DHA raw milk in improving the variety and content of phospholipid DHA in cow milk and cow milk rich in phospholipid DHA. The adopted native DHA raw milk is natural raw milk containing DHA, the phospholipid type DHA of the raw milk is various, the raw milk contains special phosphatidylinositol type DHA (PI-DHA) and cardiolipin type DHA (CLs-DHA), the proportion of phosphatidylserine type DHA (PS-DHA) is obviously higher than that of fish oil and algae oil source DHA milk, the proportion of total phospholipid type DHA in total DHA is obviously higher than that of other fish oil and algae oil DHA milk, and the DHA milk is rich in DHA, rich in DHA and rich in DHA. By adopting the original DHA raw milk to prepare cow milk, the variety and content of phospholipid type DHA of the cow milk can be increased.

Provided herein is a method for treating oral cancer in an individual. According to an embodiment of the present disclosure, the method includes obtaining a first and a second biological sample from a lesion site and a non-lesion site of the individual, respectively; measuring the expression levels of CHEK1, PIK3CA or PIK3CD in the two biological samples by qRT-PCR, respectively, thereby obtaining a first and a second expression level; determining the ratio of the first expression level to the second expression level; and administering an effective amount of a checkpoint kinase 1 inhibitor to the individual when the ratio of CHEK1 is at least 1.7; or administering a phosphatidylinositol 3-kinase inhibitor when the ratio of PIK3CA is at least 2.4, or when the ratio of PIK3CD is at least 3.1.

The invention discloses a biosynthetic gene cluster of a polyene macrolide natural product mandimycin as well as a natural product and application of the biosynthetic gene cluster. The nucleotide sequence of the biosynthetic gene cluster of the mandimycin is shown as SEQ ID NO.1, and the compound structural formulas of the natural product mandimycin and mandimycin B are shown as a formula I and a formula II. The natural product mandimycin can target fungal cell membrane phospholipid molecules, especially phosphatidylinositol, so that important ions in fungal cells are discharged, and fungal cell death is caused. The natural products mandimycin and mandimycin B disclosed by the invention have strong in-vivo and in-vitro antibacterial activity and broad-spectrum antibacterial spectrum on multiple drug-resistant fungus key pathogens published by WHO (World Health Organization), such as candida, aspergillus, cryptococcus, mucor and fusarium bacteria.

The present application belongs to the technical field of yeast extract, and particularly relates to a yeast phospholipid and a preparation method thereof. The preparation method of the yeast phospholipid comprises the following steps: (1) dispersing yeast raw materials in an alcohol solution, then performing solid-liquid separation to obtain an extraction solution; (2) concentrating the extraction solution, then dispersing the extraction solution in an extraction solvent to perform extraction, separation, and concentrating a heavy phase solution to obtain the yeast phospholipid. In terms of the total mass of the yeast phospholipid, the crude fat contains 10% to 40% of phosphatidylcholine, 10% to 30% of phosphatidylethanolamine, and 1% to 10% of phosphatidylinositol. The preparation method of the present application extracts yeast raw materials by using a single solvent, is convenient for recovery, reduces the extraction cost, has higher extraction efficiency of the obtained phospholipid, has higher contents of phosphatidylcholine, phosphatidylethanolamine and phosphatidylinositol, has higher content of unsaturated fatty acids, and is suitable for industrialized production.

The invention discloses a starch film slow-release patch for promoting wound healing and a preparation method thereof.The method comprises the steps that 1, silymarin, centella asiatica extract, aescin, aloe polysaccharide, lithospermum erythrorhizon extract, olive oil, lecithin and cetostearyl alcohol polyether are taken and mixed to be uniform, phosphatidylinositol and deionized water are added, low-speed stirring and high-speed shearing are conducted in sequence at the temperature of 25-35 DEG C, and the starch film slow-release patch for promoting wound healing is obtained; the microcrystal nano-emulsion is obtained; 2, adding gelatin and starch into deionized water, heating for 5-15 minutes at 60-80 DEG C while stirring, cooling to 40-50 DEG C, adding citric acid, calcium citrate, glycerol, ethylene glycol and the crystal nano-emulsion, and uniformly mixing to obtain mixed paste liquid; 3, the mixed paste liquid is contained in a vacuumizing container, vacuumizing is conducted, and degassed mixed paste liquid is obtained; 4, carrying out roll forming on the mixed paste to obtain a starch film; and 5, cutting the starch film into the starch film slow-release patch. The starch film sustained-release patch prepared by the invention has good flexibility, viscosity and air permeability, and is capable of stopping bleeding, resisting inflammation and promoting wound healing.

The invention discloses a Listeria monocytogenes chromogenic culture medium formula and a preparation method thereof, and the Listeria monocytogenes chromogenic culture medium formula comprises the following components in proportion: 7%-7.3% of a Listeria monocytogenes basic culture medium, 0.2%-0.8% of powdery phospholipid, 2.5% of a bacteriostatic agent and the balance of purified water; the preparation method comprises the following steps: step 1, weighing and dissolving; step 2, high-pressure sterilization; 3, mixing the solutions; and step 4, subpackaging a flat plate. According to the listeria chromogenic medium formula and the preparation method thereof, the powdery phospholipid is adopted to replace traditional phosphatidylinositol, and the price of the powdery phospholipid is far lower than that of the phosphatidylinositol, so that the manufacturing cost of the listeria chromogenic medium is remarkably reduced, and the purpose of saving the cost is achieved.

The application provides a traditional Chinese medicine preparation for improving myopia, a gel base and a preparation method thereof. The traditional Chinese medicine preparation for improving myopia comprises the gel base, a traditional Chinese medicine extract; the gel base comprises a drug carrier, a gel skeleton and a pharmaceutical excipient; the drug carrier is a complex formed by cationic cyclodextrin and phosphatidylinositol; the gel skeleton is obtained by crosslinking sodium polyacrylate and gallium hydroxyaluminum; and the pharmaceutical excipient comprises hydroxypropyl methylcellulose, polyvinyl alcohol, hyaluronic acid and glycerol. The traditional Chinese medicine preparation for improving myopia can effectively improve myopia and has the characteristics of high encapsulation efficiency and good stability.

The invention discloses an application of phosphatidylinositol phosphatase SAC1 in prognosis and treatment of liver cancer. The research shows that the phosphatidylinositol phosphatase SAC1 can obviously inhibit the metastasis of the hepatocellular carcinoma, and a new hepatocellular carcinoma treatment strategy is provided from the perspective of phospholipid metabolism. Therefore, the SAC1 as a novel potential target spot for anti-hepatocellular carcinoma metastasis treatment has a good application prospect.